Huizenga Theodore Alan — SEC insider filings
SEC reporting owner CIK 1603347. 32 insider filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 32 filings on record, filed 2020-10-16 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 24 legs across 22 filings — 19,746 shares, $1,507,794 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 35.
- Largest priced transaction: sale of 4,000 shares @ $140.65 ($562,600) in Ultragenyx Pharmaceutical Inc., filed 2021-01-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | SVP, Chief Accounting Officer | 32 | — | 24 legs · 19,746 sh · $1,507,794 | 35 |
Insider filings — Huizenga Theodore Alan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 1,283 @ $13.57 | EDGAR |
| 2026-09-08 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 161 @ $13.99 | EDGAR |
| 2026-04-24 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 20,241 @ $0 · Grant/award (A): 7,348 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Tax withholding (F): 148 @ $23.39 · Sale (S): 1,632 @ $22.80 | EDGAR |
| 2025-12-30 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 85 @ $34.38 | EDGAR |
| 2025-09-19 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 64 @ $29.17 | EDGAR |
| 2025-09-08 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 84 @ $31.39 | EDGAR |
| 2025-03-04 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 9,392 @ $0 · Sale (S): 967 @ $42.10 · Tax withholding (F): 141 @ $42.92 · Grant/award (A): 5,632 (derivative) @ $0 | EDGAR |
| 2024-12-11 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Gift (G): 648 @ $0 | EDGAR |
| 2024-09-18 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 700 @ $0 | EDGAR |
| 2024-09-05 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 91 @ $56.19 | EDGAR |
| 2024-04-18 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Tax withholding (F): 14 @ $42.31 | EDGAR |
| 2024-03-05 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 13,950 @ $0 · Tax withholding (F): 121 @ $53.69 · Sale (S): 341 @ $53.76 · Grant/award (A): 8,200 (derivative) @ $0 · Grant/award (A): 2,351 (derivative) @ $0 | EDGAR |
| 2024-01-02 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 1,000 @ $0 · Option exercise (M): 3,000 @ $21 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2023-09-29 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 2,351 (derivative) @ $0 | EDGAR |
| 2023-09-11 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Option exercise (M): 2,000 @ $21 · Sale (S): 2,000 @ $41 · Sale (S): 163 @ $38.34 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2023-09-06 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 883 @ $37.04 · Sale (S): 87 @ $38.23 | EDGAR |
| 2023-05-10 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Option exercise (M): 3,000 @ $21 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Tax withholding (F): 14 @ $38.20 · Disposition to issuer (D): 181 @ $38.20 | EDGAR |
| 2023-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 7,590 @ $0 · Sale (S): 100 @ $45.65 · Disposition to issuer (D): 1,333 @ $45.65 · Grant/award (A): 10,120 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 639 @ $43.40 | EDGAR |
| 2022-12-22 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 2,031 @ $43.96 | EDGAR |
| 2022-09-08 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 1,000 @ $0 | EDGAR |
| 2022-04-19 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 132 @ $84.55 | EDGAR |
| 2022-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 843 @ $66.62 · Grant/award (A): 3,710 @ $0 · Grant/award (A): 7,400 (derivative) @ $0 | EDGAR |
| 2021-10-18 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Gift (G): 819 @ $0 · Sale (S): 140 @ $81.14 | EDGAR |
| 2021-05-10 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 142 @ $113.67 | EDGAR |
| 2021-04-19 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2021-03-09 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 3,000 @ $120.69 | EDGAR |
| 2021-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 1,560 @ $0 · Sale (S): 732 @ $138.17 · Grant/award (A): 4,655 (derivative) @ $0 | EDGAR |
| 2021-01-08 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Option exercise (M): 4,000 @ $21 · Sale (S): 4,000 @ $140.65 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2020-10-16 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 146 @ $87.98 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1603347 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs